Status | Study |
Recruiting |
Study Name: Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Condition: Germ Cell Tumor Nonseminomatous Germ Cell Tumor Seminoma Date: 2017-05-16 Interventions: Drug: Durvalumab 1500 mg by IV |
Active, not recruiting |
Study Name: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Condition: Cognitive Side Effects of Cancer Therapy Malignant Ovarian Epithelial Tumor Date: 2010-03-03 Interventions: Procedure: Cognitive Assessment |
Completed |
Study Name: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors Condition: Brain and Central Nervous System Tumors Extragonadal Germ Cell Tumor Date: 2007-05-03 Interventions: Biological: pegfilgrastim Drug: cisplatin |
Completed |
Study Name: Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Condition: Extragonadal Germ Cell Tumor Ovarian Cancer Teratoma Date: 2007-03-27 Interventions: Drug: sunitinib malate |
Completed |
Study Name: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Condition: Bladder Cancer Brain and Central Nervous System Tumors Bre Date: 2006-04-11 Interventions: Drug: lapatinib Other Names: |
Completed |
Study Name: Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) Condition: Dysgerminoma Date: 2005-09-13 Interventions: Drug: Darbepoetin alfa |
Terminated |
Study Name: Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer Condition: Ovarian Dysgerminoma Recurrent Malignant Testicular Germ Cell T Date: 2002-08-05 Interventions: Drug: imatinib mesylate Given |